Ventus Therapeutics
Company Information
Ventus Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule medicines for inflammatory and immune-mediated disease. Public materials highlight its ReSOLVE® structural biology and computational chemistry platform and pipeline programs directed at innate immune targets. Its disclosed lead assets include NLRP3 and cGAS inhibitors being developed for neurological, inflammatory, and autoimmune indications.
Industry Focus and Technologies
Drug discovery, small-molecule therapeutics, innate immunity, inflammasome biology, structural biology, computational chemistry.
Location
Saint-Laurent, Quebec, Canada
Company Size and Stage
Products, Platforms or Focus Areas
ReSOLVE® discovery platform, VENT-02 brain-penetrant NLRP3 inhibitor, VENT-03 oral cGAS inhibitor, and additional small-molecule programs targeting inflammatory pathways.